Dakang Medical operates a network of independent medical facilities specializing in blood purification services for kidney disease. The company focuses on providing advanced treatments such as hemodialysis, hemofiltration, and peritoneal dialysis, utilizing state-of-the-art medical technology. Dakang Medical emphasizes a patient-centered approach, aiming to create a warm and supportive environment to enhance the treatment experience for individuals suffering from nephropathy. In addition to its clinical services, Dakang Medical is involved in medical investment and the management of medical institutions, as well as offering brand operation services within the healthcare sector.
TBSTest Technology is a developer and manufacturer of integrated circuit automatic test equipment, specializing in solutions for semiconductor manufacturers. Founded in 2017 and headquartered in Beijing, China, with additional offices in Xi’an City, Shanghai, and Suwon, South Korea, the company offers a range of products including test boards, software solutions, and memory systems. TBSTest Technology also provides pre-sales and after-sales support for its equipment, accessories, and software systems, catering to clients in integrated circuit design and production, as well as scientific research institutions and educational organizations. The company is dedicated to advancing testing technology for ultra-large-scale integrated circuits, ensuring high-quality performance for enterprise users in the semiconductor industry.
Yihui Information is a high-tech enterprise with complete independent intellectual property rights
Private Equity Round in 2022
G7 has an installation base of 800,000 cargo vehicles throughout China. Through its proprietary hardware devices, the company is able to compile data for logistics companies and drivers on location, route optimization, fuel consumption, and cargo status (temperature, humidity, etc).
Sinomicro Medical is a medical device firm focused on the development of tumor ablation treatment with minimally invasive surgical robots.
ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.
Biocytogen is a biotechnology company specializing in the development of gene-engineered animal models for life sciences research. Founded in 2008 and headquartered in Beijing, with additional locations in the United States, Biocytogen offers a range of preclinical animal studies utilizing various advanced models, including gene humanized and patient-derived xenograft (PDX) models. Its product portfolio features numerous genetically modified mouse and rat models designed for research in areas such as tumor immunity, autoimmunity, and pharmacology. The company also provides customized gene-targeting services, phenotype analysis, and an antibody research and development platform. By integrating resources from both China and the U.S., Biocytogen aims to be a leading supplier of gene-targeted animal models and services globally.
HQ Education is an O2O education service platform.
Private Equity Round in 2019
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Biocytogen is a biotechnology company specializing in the development of gene-engineered animal models for life sciences research. Founded in 2008 and headquartered in Beijing, with additional locations in the United States, Biocytogen offers a range of preclinical animal studies utilizing various advanced models, including gene humanized and patient-derived xenograft (PDX) models. Its product portfolio features numerous genetically modified mouse and rat models designed for research in areas such as tumor immunity, autoimmunity, and pharmacology. The company also provides customized gene-targeting services, phenotype analysis, and an antibody research and development platform. By integrating resources from both China and the U.S., Biocytogen aims to be a leading supplier of gene-targeted animal models and services globally.
Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Beijing Zettastone Technology Co., Ltd. is a company based in Beijing, China, specializing in the development of solid-state drives (SSDs). The company focuses on creating SSDs that cater to the needs of personal computer manufacturers, data centers, and storage solution providers. By providing advanced storage technology, Zettastone aims to enhance performance and efficiency for its customers, offering solutions that are both easier to use and faster than traditional storage options.
Cambricon Technologies Corporation Limited creates core processor chips for various types of intelligent cloud servers, intelligent edge devices, and intelligent terminals. It offers terminal intelligent processor IPs, smart accelerator cards, and edge artificial intelligence acceleration cards; and Cambricon NeuWare, a software development platform for its cloud, edge, and end intelligent processor products. The company was founded in 2016 and is based in Beijing, China.
Robotleo manufactures robots for domestic use. The company was founded in 2014 and is based in Beijing, China.
Biocytogen is a biotechnology company specializing in the development of gene-engineered animal models for life sciences research. Founded in 2008 and headquartered in Beijing, with additional locations in the United States, Biocytogen offers a range of preclinical animal studies utilizing various advanced models, including gene humanized and patient-derived xenograft (PDX) models. Its product portfolio features numerous genetically modified mouse and rat models designed for research in areas such as tumor immunity, autoimmunity, and pharmacology. The company also provides customized gene-targeting services, phenotype analysis, and an antibody research and development platform. By integrating resources from both China and the U.S., Biocytogen aims to be a leading supplier of gene-targeted animal models and services globally.
KBP Biosciences Co., Ltd. is a biotechnology company based in Jinan, China, with additional offices in Beijing, Japan, and the United States. Founded in 2002, the company focuses on the research and development of drugs targeting infectious and metabolic diseases. Its comprehensive research platform employs structure-based drug design, in vitro and cell-based biological screening, and pharmacodynamic and pharmacokinetic evaluation, alongside ADME profiling and pre-clinical animal pharmacology and toxicity analysis. KBP Biosciences also offers services related to the transfer of new drugs, licensing, and intellectual property protection, which includes patent scope analysis, novelty analysis, and patent writing and filing. The organization is committed to delivering innovative therapies to address unmet medical needs.
Enmotech (Beijing) Information Technology Co., Ltd. provides solutions and professional services for data/database systems and related areas. The company’s products and services include security, performance optimization, integration, and others. It also offers technical services, such as distributed architecture, high availability disaster recovery, SQL audit, operation and maintenance, performance monitoring, professional training, and data model optimization. In addition, the company provides software that comprise Bethune, an IT system health automated inspection platform; zCloud database cloud service management platform; SQM – SQL quality control platform; zData database machine; and MyData, an automated operation and maintenance management platform. It serves customers in financial services, communication operation, energy transportation, government/public utility, and manufacturing/trade markets. The company was founded in 2009 and is based in Beijing, China.
Cambricon Technologies Corporation Limited creates core processor chips for various types of intelligent cloud servers, intelligent edge devices, and intelligent terminals. It offers terminal intelligent processor IPs, smart accelerator cards, and edge artificial intelligence acceleration cards; and Cambricon NeuWare, a software development platform for its cloud, edge, and end intelligent processor products. The company was founded in 2016 and is based in Beijing, China.
Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.
HiGo is a developer of intelligent driving control systems that aims to provide comprehensive solutions for autonomous vehicles. The company specializes in hardware, focusing on a central computing platform and chassis domain control platform. HiGo has positioned itself as a leader in the industry by launching self-driving electric sweepers designed for low-speed and fixed scenarios in China. This initiative not only showcases the company's technological capabilities but also contributes to the advancement of the autonomous driving sector.
Beijing SkyGuard Network Security Technologies LLC provides network information security technology services. The company was founded in 2015 and is based in Beijing, China.
Biocytogen is a biotechnology company specializing in the development of gene-engineered animal models for life sciences research. Founded in 2008 and headquartered in Beijing, with additional locations in the United States, Biocytogen offers a range of preclinical animal studies utilizing various advanced models, including gene humanized and patient-derived xenograft (PDX) models. Its product portfolio features numerous genetically modified mouse and rat models designed for research in areas such as tumor immunity, autoimmunity, and pharmacology. The company also provides customized gene-targeting services, phenotype analysis, and an antibody research and development platform. By integrating resources from both China and the U.S., Biocytogen aims to be a leading supplier of gene-targeted animal models and services globally.
Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.
Twenty First Century Aerospace Technology Co., Ltd operates commercial earth observation (EO) satellites, and provides data and information services. The company operates EO small satellites, including the 1m optical EO small satellite constellation, and satellite control and image tasking and receiving stations. It provides products and services for the entire space geo-information value chain that range from satellite procurement/financing, satellite housekeeping, payload and satellite resources management, tasking, data acquisition, image processing, hosting/archiving, data management/distribution, multiple satellite source integration through its Web portal, and geo-information services to application software development and integrated solutions. The company offers imaging data, including programmed and archiving data; value added images, geo-information services, and spatial remote sensing services; image data processing software, database, Web portal development, smart satellite resource management and operation, and automatic and intelligent tasking software development, as well as direct image receiving. Its geo-information services cover a range of information products and services; including land cover theme imagery, change investigation, data statistics and analysis, 3D simulation, and professional consultancy for spatial information applications to serve government administration, public services, and commercial markets. The company also provides information extraction, operational monitoring, system platform, and ground station services. Its solutions are used for intelligence city management, living resources, energy and natural resources, eco-environment, disaster and emergency response, and industrial applications. The company was founded in 2001 and is based in Beijing, China.